Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

520 TACROLIMUS
Other
Anaphylactoid reactions/Anaphylaxis (10%)
(2005): Hanifin JM+, JAmAcadDermatol53(2 Suppl 2), S186
Myalgia/Myositis/Myopathy/Myotoxicity (>3%)
Nephrotoxicity
(2007): Tse KC+, Lupus 16(1), 46 (1 case)
(2006): Boger CA+, Am J Transplant 6(8), 1963
(2006): Borrows R+, Ther Drug Monit 28(2), 269 (6 cases)
(2006): Dittrich K+, Pediatr Nephrol 21(7), 958
(2006): Froud T+, Cell Transplant 15(7), 613
(2006): Ruddock B, Issues Emerg Health Technol 88, 1
(2006): Ueno T+, Transplant Proc 38(6), 1762
(2005): McLaughlin GE+, NephrolDialTransplant20(7), 1471
(2004): Kuypers DR+, Clin Pharmacol Ther 75(5), 434
(2003): Flechner SM, Transplant Proc 35(3 Suppl), 118S
(2002): Barone GW+, JOP 3(2), 49
(2002): Bolley R+, Transplantation 73(6), 1009
(2002): Khanna A+, Kidney Int 62(6), 2257
(2002): Lytton SD+, Clin Exp Immunol 127(2), 293
(2001): Morales JM+, NephrolDialTransplant16 Suppl 1, 121
(2001): Pescovitz MD+, Am J Kidney Dis 38(4 Suppl 2), S16
(2001): Venkataramanan R+, J Clin Pharmacol 41(5), 542
(2001): Wondimu B+, Int J Paediatr Dent 11(6), 424
(2000): de Mattos AM+, Am J Kidney Dis 35(2), 333
(2000): Emre S+, Transpl Int 13(s), 73
(2000): Yanik G+, Bone Marrow Transplant 26(2), 161
(1999): Finn WF, Ren Fail 21(3–4), 319
(1999): Soccal PM+, Transplantation 68(1), 164
(1999): Zoppo A+, Transplantation 68(8), 1211
(1998): Heering P+, Clin Transplant 12(5), 465
(1998): Solez K+, Transplantation 66(12), 1736
(1997): Duddridge M+, Ann Rheum Dis 56(11), 690
(1997): Filler G+, NephrolDialTransplant12(8), 1668
(1997): Katari SR+, Clin Transplant 11(3), 237
(1997): Katari SR+, Transplant Proc 29(1–2), 311
Neurotoxicity
(2007): Kaczmarek I+, J Heart Lung Transplant 26(1), 89
(2006): Froud T+, Cell Transplant 15(7), 613
(2001): Wondimu B+, Int J Paediatr Dent 11(6), 424
(2000): Emre S+, Transpl Int 13(s), 73
Pain
(2002): Malat GE+, Pediatr Transplant 6(5), 435
Tumors
(2007): Levi Z+, Am J Transplant 7(2), 476 (facial)
TADALAFIL
Trade name: Cialis (Lilly-ICOS)
Indications: Erectile dysfunction
Category: Phosphodiesterase type 5 inhibitor
Half-life: 17.5 hours
Clinically important, potentially hazardous interactions
with: alpha-II-blockers, doxazosin, ketoconazole, nicorandil,
nitrates, ritonavir
Reactions
Skin
Diaphoresis (